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and require renal replacement therapy, the latter being 
associated with signifi cant mortality, a lower quality of 
life, and high costs for national health systems. Thus, new 
treatment strategies that slow down, halt or even revert 
progressive renal damage are requested. Current treat-
ments for chronic renal failure target to correct renal he-
modynamics, proteinuria, high blood pressure, hyper-
parathyroidism or to avoid nephrotoxic drugs and nico-
tine abuse. A general role of immunosuppressive drugs in 
chronic kidney disease is not established, because of lack 
of effi cacy or unacceptable side effects of systemic immu-
nosuppression. 
 Many types of chronic kidney diseases are character-
ized by an accumulation of interstitial leukocytes. Infi l-
trating leukocytes are a major source for proinfl amma-
tory and profi brotic cytokines and are therefore critical 
for mediating fi broblast proliferation, differentiation into 
myofi broblasts, matrix production, and tubular atrophy 
 [1] . Thus, interfering with renal leukocyte recruitment 
may represent a valuable strategy to reduce renal infl am-
mation, tissue remodeling, and progressive loss of renal 
function. During the past decade we and others have un-
raveled the role of chemokines and chemokine receptors 
that direct circulating leukocytes into the damaged kid-
ney, which was recently reviewed in detail  [2] . In this ar-
ticle, we focus on chemokine receptor CCR1 that was 
identifi ed from a group of other chemokines to play a 
critical role for interstitial leukocyte recruitment. 
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 Abstract 
 Infi ltrating leukocytes are thought to contribute to the 
progression of kidney disease. Locally produced chemo-
kines guide circulating leukocytes into the kidney, which 
renders therapeutic blockade of respective chemokine 
receptors on the leukocyte surface as potential targets 
for the inhibition of renal leukocyte recruitment. By using 
mutant mice and specifi c antagonists, we found that che-
mokine receptor CCR1 has non-redundant functions for 
leukocyte adhesion to activated vascular endothelium 
and for transendothelial diapedesis. Most importantly, 
CCR1 blockade with a specifi c small molecule antagonist 
can improve injury in several types of progressive kidney 
disease models, even if treatment is initiated in advanced 
disease states. Identifi cation of new targets may add to 
the therapeutic options in chronic kidney disease. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 The global burden of chronic kidney diseases remains 
an ongoing medical challenge. Therapies that can halt or 
reverse advanced renal injury are not available. Increas-
ing numbers of patients progress to end-stage renal failure 
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 Chemokines and Chemokine Receptors in 
Renal Leukocyte Recruitment 
 Chemokines and Chemokine Receptors 
 Chemokines are a large family of low molecular weight 
cytokines that cause migration of leukocytes. The nomen-
clature used to describe individual chemokine ligands is 
based upon the four-cysteine motif in their amino acid 
sequence as listed in  table 1  [3] . Chemokines can be fur-
ther classifi ed according to their predominant function 
and expression pattern. For example, chemokines such as 
CCL21 or CCL19 are classifi ed as homeostatic chemo-
kines. They are involved in physiological homing of leu-
kocytes to lymphoid tissues  [4, 5] , and in lymphocyte and 
dendritic cell traffi cking during immune surveillance  [6] . 
Chemokines such as CCL2, CCL3, CCL5, and CXCL10 
are classifi ed as proinfl ammatory chemokines because 
they mediate the recruitment of leukocytes to sites of tis-
sue injury  [7, 8] . Chemokines can interact with only one 
receptor or a single chemokine binds to multiple receptors 
 [8] . 
 Chemokines mediate their biologic actions through a 
family of more than 20 seven-transmembrane-spanning 
G-protein-coupled receptors  [4, 9, 10] . Chemokine recep-
tors are designated according to the class of their che-
mokine ligands, e.g. CR, CCR, CXCR, and CX3CR ( ta-
ble 1 ). Chemokine receptors show restricted expression 
on subclasses of leukocytes. Because the ligand specifi ci-
ties of the receptors can substantially overlap within a 
chemokine class, a high degree of redundancy of single 
chemokines was suspected  [5, 8] . In general, the proin-
fl ammatory chemokine receptors have promiscuous li-
gand binding specifi cities. This fi nding gave rise to the 
concept that blocking chemokine receptors could repre-
sent a rational approach to target the chemokine system 
rather than targeting a single chemokine. 
 Chemokines and Chemokine Receptors Mediate 
Leukocyte-Endothelial Cell Interactions 
 Chemokines are involved in the interactions of leuko-
cytes and activated endothelial cells at multiple stages  [5, 
11] . Injured renal cells produce infl ammatory mediators 
that enhance the expression of adhesion molecules on 
endothelial cells of capillaries adjacent to the infl amma-
tory lesion. Selectins mediate the rolling process of leuko-
cytes along the endothelial surface and thereby allow con-
tact of leukocytes with chemokines. The Duffy antigen 
receptor for chemokines (DARC) can bind chemokines 
Ligand Receptors Ligand Receptors
CXCL1 Gro CXCR1, 2 CCL1 I-309 CCR8
CXCL2 Gro CCL2 MCP-1 CCR2
CXCL3 Gro CCL3 MIP-1 CCR1, 5
CXCL4 PF4 CXCR1, 2 CCL4 MIP-1 CCR5
CXCL5 ENA-78 CXCR2 CCL5 RANTES CCR1, 3, 5
CXCL6 GCP-2 CXCR1, 2 CCL7 MCP-3 CCR1, 2
CXCL7 NAP-2 CXCR2 CCL8 MCP-2 CCR1, 2, 5
CXCL8 IL-8 CXCR1, 2 CCL11 Eotaxin CCR3
CXCL9 Mig CXCR3 CCL13 MCP-4 CCR1, 2, 3
CXCL10 IP-10 CXCR3 CCL14 HCC-1 CCR1
CXCL11 I-TAC CXCR3 CCL15 HCC-2 CCR1
CXCL12 SDF-1 CXCR4 CCL16 HCC-4 CCR1, 8
CXCL13 BCA-1 CXCR5 CCL17 TARC CCR4
CXCL14 Bolekine CCL18 DC-CK1
CXCL15 Lungkine CCL19 ELC CCR7
CCL20 LARC CCR6
XCL CCL21 SLC/6Ckine CCR7
XCL1 Lymphotactin XCR1 CCL22 MDC CCR4
XCL2 SCM-1 CCL23 MPIF-1 CCR1
CCL24 Eotaxin-2 CCR3
CCL25 TECK CCR9
CX3CL CCL26 Eotaxin-3 CCR3
CX3CL1 Fractalkine CX3CR1 CCL27 CTAK/Eskine CCR10
 
 Table 1. Classifi cation of chemokines and 
chemokine receptors 
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at post-capillary venules  [12] . However, in various forms 
of renal diseases, DARC expression expands to peritubu-
lar vessel endothelium and thereby marks specifi c exit 
sites for leukocytes into the renal interstitium  [12] . Che-
mokines ligate their respective receptors on the surface of 
the rolling leukocyte. This activates leukocyte-expressed 
  2 -integrins, resulting in fi rm adhesion of the leukocyte 
to the endothelial surface as a prerequisite for leukocyte 
transmigration  [5, 7, 13] . Other chemokine receptors ap-
pear to differentially infl uence spreading, diapedesis, and 
subsequent migration into the tissue space  [5, 14] . For 
example, monocytes and T cells express both chemokine 
receptors CCR1 and CCR5  [15] . In an in vitro system it 
was found that immobilized CCL5 induced leukocyte ar-
rest via CCR1, while leukocyte spreading was mediated 
via CCR5, and transendothelial migration was supported 
by both receptors  [15] . In this context it is of interest that 
chemokines also modulate the redistribution of junction-
al adhesion molecules at endothelial cell tight junctions 
that may promote leukocyte diapedesis by transient open-
ing of focal cell-cell contacts  [16] . Furthermore, CCL5 
up-regulates the secretion and activity of matrix metal-
loproteinases by infi ltrating leukocytes  [17] , thus facilitat-
ing leukocyte transmigration through the basement mem-
brane and extracellular matrix  [18] . 
 Chemokines and Chemokine Receptors in Renal 
Infl ammation 
 All types of renal cells can produce chemokines upon 
stimulation  [ reviewed in  11] . Proinfl ammatory stimuli 
including reactive oxygen species, growth factors and va-
soactive agents like angiotensin II can stimulate chemo-
kine production of renal cells. Furthermore, immune 
complexes and complement activation cause mesangial 
production of chemokines. In proximal tubular cells, che-
mokines can be induced by LPS  [19] , high concentrations 
of albumin  [20, 21] or exposure to both calcium oxalate 
and calcium phosphate crystals  [22] . Besides intrinsic re-
nal cells, infi ltrating leukocytes are a major source of local 
chemokine production in a positive amplifi cation loop 
 [23, 24] , as chemokines secreted by infi ltrating leukocytes 
promote additional leukocyte recruitment  [25] . It is im-
portant to note that chemokine expression is restricted to 
the injured compartment of the kidney  [ reviewed in  26] . 
The spatial expression of chemokines in the kidney cor-
relates with the local accumulation of infl ammatory cell 
infi ltrates and renal damage  [2, 24] . Data from animal 
models have been confi rmed by human renal biopsy stud-
ies  [12, 27–29] . 
 Termination of the trigger injury correlates with a re-
duction of chemokine expression by intrinsic renal cells 
and infi ltrating leukocytes  [30] . As further infl ux of leu-
kocytes does not occur, the number of infi ltrating leuko-
cytes declines in parallel to the resolution of disease. It is 
important to note that termination of the chemokine sig-
nal is critical for the resolution of the infl ammatory pro-
cess. If local chemokine expression is augmented by an-
other trigger of chemokine release, a pre-existing renal 
disease may eventually progress to severe renal damage. 
For example, intercurrent infections frequently result in 
a deterioration of renal diseases including chronic trans-
plant nephropathy. The proinfl ammatory signals of bac-
terial and viral invasion are mediated by Toll-like recep-
tors (TLRs)  [31] . TLRs recognize pathogen-associated 
molecules such as LPS, peptidoglycanes, and unmethyl-
ated CpG-DNA  [31] . We recently found that injection of 
unmethylated CpG-DNA into mice with otherwise self-
limiting immune complex glomerulonephritis resulted in 
progression instead of resolution of the disease process. 
This was associated with increased chemokine expression 
and subsequent glomerular macrophage recruitment  [32] . 
Even if the triggering injury subsides, renal chemokine 
expression can be maintained by other mechanisms such 
as infection, renin-angiotensin activation, hypoxia or 
proteinuria, and contribute to persistent leukocyte infi l-
tration and tissue damage. Many studies addressed the 
functional role of single chemokines or chemokine recep-
tors in defi ned renal disease models by applying either 
neutralizing antibodies, DNA vaccination, chemokine 
receptor antagonists, or by using mutant mice  [ reviewed 
in  24] . Among those, only a few studies have adminis-
tered specifi c antagonists late in the disease process, 
which most appropriately mimics treatment of estab-
lished kidney disease. Such data is only available for spe-
cifi c blockade of CCR1. 
 Identifying CCR1 as a Target 
 Human CCR1 binds several CC chemokines, includ-
ing CCL3 ( table 1 ). The amino acid sequence of human 
CCR1 has a high degree of homology to murine CCR1 
( fi g. 1 ). However, species-specifi c pharmacodynamics 
need to be defi ned for each antagonist when to be tested 
in another species  [33] . The latter often compromises the 
interpretation of data generated in rodents that apply che-
mokine antagonists designed for the human system. 
CCR1 is expressed at low levels on T cells. By contrast, 
human and murine blood monocytes, tissue macrophages, 
neutrophils, and eosinophils express CCR1 at high levels 
 [3, 29, 34] . Upon ligation with its ligands, a conforma-
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tional change of the seven-transmembrane elements of 
CCR1 leads to intracellular activation of G-protein sub-
units. Studies using an in vitro fl ow chamber system fi rst 
identifi ed a critical role for CCR1 for adhesion of rolling 
macrophages or T cells to activated endothelium using 
established human cell lines  [15] . These fi ndings were 
validated in vivo by two approaches. First, we used intra-
vital microscopy of the cremaster muscle in mice to study 
the role of CCR1 for leukocyte rolling, fi rm adhesion, 
transendothelial migration, and interstitial migration. Ei-
ther by applying a specifi c CCR1 antagonist or perform-
ing intravital microcopy in CCR1-defi cient mice, we 
found that CCR1 is required for leukocyte adhesion and 
transendothelial migration during the recruitment pro-
cess  [35] . The coherent fi ndings in antagonist-treated 
mice or CCR1-defi cient mice argue for a non-redundant 
role of CCR1 in that processes. Because organ-specifi c 
roles of chemokines and chemokine receptors have been 
reported, studies performed on cremaster muscles do not 
allow a conclusion upon the role of CCR1 in the kidney. 
Thus, as a second approach we isolated macrophages and 
T cells from spleens of CCR1-defi cient or wild-type mice. 
After ex vivo labeling with a fl uorescence dye, cells were 
injected into mice with renal fi brosis after unilateral ure-
teral obstruction (UUO)  [36] . CCR1-defi cient macro-
phages and T cells showed markedly reduced recruitment 
to the interstitial compartment of diseased kidneys as 
compared to cells isolated from wild-type mice  [36] . 
These data show that CCR1 on macrophages and T cells 
is required for interstitial leukocyte recruitment in renal 
fi brosis in mice. 
 Compartment-Specifi c Role of CCR1 
 Human renal biopsy studies have localized renal CCR1 
expression to macrophages in glomerular and interstitial 
infl ammatory cell infi ltrates in several types of kidney 
disease  [29] . However, the presence of a receptor found 
on cells that infi ltrate the kidney does not necessarily pro-
vide evidence for its functional role in the recruitment 
process. In fact, organ- and even compartment-specifi c 
roles of chemokine receptors may occur. When we treat-
ed autoimmune MRL lpr/lpr  mice with lupus nephritis with 
BX471, a small molecule CCR1 antagonist, we noted that 
despite a marked reduction of interstitial leukocyte 
 Fig. 1. Alignment of human and mouse 
CCR1. Known or predicted helixes are 
highlighted in light gray. Known or predict-
ed   -strands are highlighted in dark gray. 
Cysteine residues are encircled. Disulfi de 
bonds is indicated by the letter ‘S’. 
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counts, the number of glomerular macrophages was not 
affected compared to vehicle-treated MRL lpr/lpr  mice 
 [37] . Cell transfer studies with labeled leukocytes revealed 
that CCR1, while critical for interstitial leukocyte recruit-
ment, is not required for their recruitment into the glo-
merular compartment of nephritic MRL lpr/lpr  mice. We 
obtained similar results in BALB/c and BKS mice with 
glomerular pathology. By contrast, we could show that 
CCR5 mediates glomerular but not interstitial macro-
phage recruitment  [23, 36] . Given the fact that CCR1 and 
CCR5 are present on circulating monocytes and T cells, 
other factors appear to determine their selective roles for 
recruitment in different microvascular beds. The interac-
tion of chemokines with their receptors requires addi-
tional molecules, e.g. respective binding sites on endo-
thelial cell proteoglycans or DARC that expose the che-
mokine to the luminal endothelial cell membrane. If 
endothelial cells of glomerular or peritubular capillaries 
expose different chemokines in mice, and if these obser-
vations hold true for the human kidney, remains a future 
goal of our ongoing research activities in this fi eld. 
 Late Onset CCR1 Antagonism with a Small 
Molecule CCR1 Blocker in Models of 
Progressive Kidney Disease 
 Acute and Chronic Renal Allograft Rejection 
 The fi rst study that used the small molecule CCR1 an-
tagonist BX471 in kidney disease was reported by Horuk 
et al.  [38] in 2001. In this study, BX471 monotherapy had 
benefi cial effects on serum creatinine levels and renal sur-
vival in a model of kidney transplantation in rabbits. 
Pathologic analysis showed that BX471 was similar to 
cyclosporine in its ability to prevent extensive infarction 
of transplanted kidneys  [38] . Furthermore, BX471 pre-
vented chronic allograft nephropathy in a Fischer 344 
into Lewis rat model of acute and chronic allograft rejec-
tion  [39] . BX471 given from day 21 to 42 after kidney 
transplantation reduced the number of ED-1-positive 
macrophages in renal allografts in association with a re-
duction of markers of renal fi brosis. 
 Obstructive Nephropathy 
 Experimental UUO represents a model for obstruc-
tive nephropathy but also allows insight into the process 
of interstitial fi brosis that is a common characteristic of 
many chronic nephropathies. UUO kidneys show in-
creased CCR1 expression as compared to their respec-
tive non-obstructed contralateral kidneys  [40] . UUO 
kidneys from mice treated with the CCR1 antagonist 
BX471 revealed a marked reduction of interstitial leu-
kocyte counts  [41] . Markers of renal fi brosis, such as in-
terstitial fi broblasts, interstitial volume, mRNA and pro-
tein expression for collagen I, were all signifi cantly re-
duced by BX471 compared to vehicle-treated controls. 
Most interestingly, the benefi cial effect was comparable 
when BX471 was given not before day 6, indicating that 
late onset of CCR1 blockade may still be effective. By 
contrast, treatment was ineffective when the drug was 
supplied only from day 0 to day 5. These data were con-
fi rmed by inducing UUO in CCR1-defi cient mice  [36] . 
Thus, we decided to further evaluate CCR1 as a potential 
target for reducing interstitial leukocyte recruitment and 
fi brosis as major factors for the process of progression to 
end-stage renal failure. 
 Immune Complex Glomerulonephritis 
 Chemokines are also involved in systemic immune re-
sponses  [3] , so that data from the UUO model may not 
apply to renal manifestations of systemic autoimmunity, 
e.g. lupus nephritis. In fact, lack of CCR1 has been re-
ported to be associated with an enhanced Th1-like im-
mune response and aggravation of nephrotoxic serum ne-
phritis  [42] . We therefore studied the effects of therapeu-
tic CCR1 blockade in progressive lupus-like immune 
complex glomerulonephritis of MRL lpr/lpr  mice. BX471 
treatment initiated late during the course of disease 
(weeks 20–24 of age) improved blood urea nitrogen levels 
and reduced the amount of macrophages and lympho-
cytes in the interstitium  [37] . Furthermore, BX471 re-
duced the extent of interstitial fi brosis as evaluated by 
interstitial smooth muscle actin expression and collagen 
I deposits, as well as mRNA expression for collagen I and 
TGF-  1 . BX471 did not affect serum DNA autoantibod-
ies despite potential roles of CC chemokines and their 
receptors in systemic immune responses. As CCR1 block-
ade does not reduce glomerular macrophage recruitment, 
it was found to be ineffective in modulating glomerular 
pathology and proteinuria in MRL lpr/lpr  mice. 
 Focal Segmental Glomerulosclerosis 
 Proteinuria represents a major prognostic factor for 
the progression of renal disease, because unselective pro-
teinuria can induce chemokine expression in renal tubu-
lar cells  [43] . Thereby proteinuria serves as a major factor 
for tubulointerstitial infl ammation. Thus, we questioned 
whether CCR1 antagonism would be able to improve in-
terstitial fi brosis in the presence of massive proteinuria 
caused by focal segmental glomerulosclerosis (FSGS). 
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FSGS was induced in BALB/c mice by two intravenous 
injections of adriamycin at day 0 and 14. BX471 was 
started from day 14 when nephrotic syndrome was estab-
lished. Again, BX471 reduced the amount of interstitial 
macrophages and T cells and markers of renal fi brosis 
including interstitial fi broblasts and interstitial volume 
 [44] . These fi ndings demonstrate that therapeutic CCR1 
blockade is effective in the presence of heavy protein -
 uria. Consistent with our previous fi ndings, BX471 did 
not affect glomerular pathology in adriamycin-injected 
BALB/c mice. 
 Glomerulosclerosis in Alport Nephropathy 
 Alport syndrome is a common type of hereditary glo-
merulopathy leading to glomerulosclerosis with subse-
quent interstitial fi brosis progressing to end-stage renal 
disease. Disease progression has been thought to be medi-
ated mostly by non-infl ammatory factors, but recent stud-
ies have documented the role of interstitial macrophages 
for tubular atrophy in collagen4A3–/– mice, with renal 
lesions comparable to humans  [45] . We treated col-
lagen4A3–/– mice with BX471 or vehicle beginning from 
6 weeks of age for 4 weeks  [35] . Vehicle-treated col-
lagen4A3–/– mice showed a mean survival of 69 days 
(95% confi dence interval, 64–74 days), whereas daily 
treatment with BX471 from week 6 increased mean sur-
vival to 86 days (95% confi dence interval, 80–92 days;
p = 0.0002). BX471 treatment was associated with less 
interstitial macrophages, apoptotic tubular epithelial 
cells, tubular atrophy, interstitial fi brosis, and less glob-
ally sclerotic glomeruli as compared to vehicle-treated 
mice. In contrast, BX471-treated collagen4A3–/– mice 
showed a higher density of peritubular capillaries. Obvi-
ously, blocking CCR1-mediated interstitial macrophage 
recruitment can maintain peritubular microvasculature 
and prevent tubular atrophy, two major factors for dis-
ease progression in infl ammatory and non-infl ammatory 
types of progressive nephropathies. These data also indi-
cate the crucial role of macrophage infi ltrates for the pro-
gression of chronic kidney disease. 
 Diabetic Nephropathy 
 Diabetic nephropathy is the most common type of 
chronic kidney disease progressing to renal failure. Avail-
able rodent models of diabetic nephropathy are frequent-
ly used to study the early glomerular changes of diabetic 
nephropathy  [46] . However, rodents usually do not de-
velop advanced interstitial lesions as they occur in late 
stages of human diabetic nephropathy  [47] . Recently, 
Chow et al.  [48] reported that db/db mice develop sig-
nifi cant interstitial macrophage infi ltrates at 6 months of 
age. We injected male db/db mice from 5 months of age 
for 10 days and obtained renal tissue for histopathologi-
cal analysis. BX471 reduced the number of macrophages 
in the renal interstitium as compared to vehicle-treated 
db/db mice [unpubl. observation], supporting the hy-
pothesis that blocking interstitial macrophage recruit-
ment with CCR1 antagonists may be benefi cial also in 
diabetic nephropathy. 
 In summary, CCR1 blockade can effectively prevent 
recruitment of monocytes and lymphocytes into the renal 
interstitium. BX471 is effective in multiple models of 
progressive kidney disease in mice even when treatment 
was started late in the disease process. Thus, interfering 
with renal leukocyte recruitment by targeting CCR1 may 
represent a promising strategy to prevent disease progres-
sion in chronic nephropathies characterized by intersti-
tial leukocytic cell infi ltrates. 
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